Protalix BioTherapeutics
PLX
33 hedge funds and large institutions have $21.2M invested in Protalix BioTherapeutics in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
6% more funds holding
Funds holding: 31 → 33 (+2)
0.06% less ownership
Funds ownership: 2.67% → 2.6% (-0.06%)
22% less capital invested
Capital invested by funds: $27.1M → $21.2M (-$5.9M)
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $27K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$40.9K |
| 2 |
Renaissance Technologies
New York
|
+$29.1K |
| 3 |
HSBC Holdings
London,
United Kingdom
|
+$12.9K |
| 4 |
FANJ
Financial Architects (New Jersey)
Marlton,
New Jersey
|
+$8.57K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$265K |
| 2 |
SIM
Spark Investment Management
New York
|
-$103K |
| 3 |
Morgan Stanley
New York
|
-$98.4K |
| 4 |
Jane Street
New York
|
-$88.2K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$49.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Morgan Stanley
New York
| $1K | -$98.4K | -11,484 | -99% |
|
27
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
28
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$265K | -25,950 | Closed |
|
|
TC
29
TFS Capital
West Chester,
Pennsylvania
| – | -$32K | -3,123 | Closed |
|
30
Barclays
London,
United Kingdom
| – | -$16.2K | -1,885 | -3% |
|
31
UBS Group
Zurich,
Switzerland
| – | -$257 | -30 | -38% |
|
32
Simplex Trading
Chicago,
Illinois
| – | +$111 | +13 | New |
|
33
Group One Trading
Chicago,
Illinois
| – | +$317 | +37 | New |
|
PLX Hedge Fund Activity: Q1 2016 in Review
33 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2016, worth a combined $21.2M — down 22% from $27.1M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PLX positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 10 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $40.9K. The largest seller was State of Wisconsin Investment Board, exiting entirely with an estimated $265K sold.
- 33 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2016, up from 31 in Q4 2015.
- Funds reported $21.2M of Protalix BioTherapeutics stock for Q1 2016, down 22% quarter-over-quarter.
- 4 funds opened new Protalix BioTherapeutics positions in Q1 2016 and 2 closed out, a net change of +2 holders.
- The largest Protalix BioTherapeutics buyer in Q1 2016 was Broadfin Capital, an estimated $40.9K added.
- The largest Protalix BioTherapeutics seller in Q1 2016 was State of Wisconsin Investment Board, an estimated $265K sold.
Based on aggregated 13F filings for Q1 2016.